Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlick, Anna C, Ariyan, Charlotte E, Buchbinder, Elizabeth I, Davar, Diwakar, Gibney, Geoffrey T, Hamid, Omid, Hieken, Tina J, Izar, Benjamin, Johnson, Douglas B, Kulkarni, Rajan P, Luke, Jason J, Mitchell, Tara C, Mooradian, Meghan J, Rubin, Krista M, Salama, April KS, Shirai, Keisuke, Taube, Janis M, Tawbi, Hussein A, Tolley, J Keith, Valdueza, Caressa, Weiss, Sarah A, Wong, Michael K, Sullivan, Ryan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603365/
https://www.ncbi.nlm.nih.gov/pubmed/37852736
http://dx.doi.org/10.1136/jitc-2023-006947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603365/
https://www.ncbi.nlm.nih.gov/pubmed/37852736
http://dx.doi.org/10.1136/jitc-2023-006947

Ejemplares similares